Roivant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts development in CLE
ROIV•Secondary signals and development plans
Secondary measures showed encouraging directional signals, particularly in patients with stronger biological responses.
Development in cutaneous lupus will be halted, citing the overall readout and a competitive market backdrop.
Safety was described as favorable, with other IMVT-1402 programs kept on their existing clinical timelines.
Topline results from cutaneous lupus study
Roivant reported topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus.
Results have already been presented as topline data, showing the trial missed its main efficacy goal versus placebo.
